Pilatus Biosciences
1 known investors
Pilatus Biosciences develops first-in-class antibodies and bifunctional proteins that target metabolic checkpoints to reprogram the immune microenvironment for treating cancer and immune-related diseases. Its lead candidate, an anti-CD36 monoclonal antibody, is in Phase 1 clinical trials for advanced solid tumors.
BiotechDeep TechHealthtech
Founders & leadership
RL
Raven LinCo-Founder & CEO
Investors · 1
Frequently asked questions
- What does Pilatus Biosciences do?
- Pilatus Biosciences develops first-in-class antibodies and bifunctional proteins that target metabolic checkpoints to reprogram the immune microenvironment for treating cancer and immune-related diseases. Its lead candidate, an anti-CD36 monoclonal antibody, is in Phase 1 clinical trials for advanced solid tumors.
- Who are Pilatus Biosciences's investors?
- Pilatus Biosciences's investors include Mosaic Venture Lab.